In the SURPASS-2 trial, patients with obesity and T2D who received tirzeapatide (5 mg weekly) achieved greater HbA1c and body weight reductions than those receiving semaglutide (1 mg weekly) during the 40 week study ( With these points in mind, we undertook a broad assessment of published clinical data, curating the body weight loss (% from baseline), glycosylated hemoglobin levels (HbA1c), and nausea responses (% patients reporting) from the SUSTAIN 3, SUSTAIN 7, SCALE Diabetes, SURPASS 2, and STEP 2 trials ( Figures 1AC )
Brendan Camp, MD, is a double board-certified dermatologist in dermatology and dermatopathology at MDCS Dermatology in New York
Munich Re Life medical experts Dr
Mitra S, Behbahani H, Eriksdotter M
Call 480.575.6584
In some embodiments, the otic formulation comprises between about 0.0001% to about 20% by weight of the weight of the therapeutic agent, or pharmaceutically acceptable prodrug or salt thereof